Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

89.10 +0.49 (+0.55%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
News headline image
AstraZeneca Showcases Strength of Hematology Portfolio and Pipeline Across Multiple Hard-to-Treat Conditions at ASH 2022
From AstraZeneca
Via Business Wire
News headline image
C4X Discovery Holdings plc: C4XD signs exclusive global licence worth up to $402 million¹ with AstraZeneca for the development and commercialisation of NRF2 Activator programme
From C4X Discovery Holdings plc
Via GlobeNewswire
News headline image
AstraZeneca Aims to Redefine Breast Cancer Care With New Data Across the Treatment Spectrum At SABCS 2022
From AstraZeneca
Via Business Wire
News headline image
Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics
From Alexion, AstraZeneca Rare Disease
Via Business Wire
News headline image
IMFINZI and IMJUDO with chemotherapy approved in the US for patients with metastatic non-small cell lung cancer
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca EVUSHELD Named on TIME’s List of the Best Inventions of 2022
From AstraZeneca
Via Business Wire
News headline image
PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma
From AstraZeneca
Via Business Wire
News headline image
ULTOMIRIS® (ravulizumab-cwvz) showed zero relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) with median treatment duration of 73 weeks
From Alexion
Via Business Wire
News headline image
Eli Lilly Dividend: Does Eli Lilly Pay Dividends?
Yes, Eli Lilly and Company (NYSE: LLY) pays dividends but there is more to investing in this stock than a simple “yes” answer. The Eli Lilly dividend is safe enough but it may not be right for all... 
Via MarketBeat
News headline image
Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer
From AstraZeneca
Via Business Wire
News headline image
Capivasertib plus FASLODEX® (fulvestrant) significantly improved progression-free survival vs. FASLODEX in CAPItello-291 Phase III trial in advanced HR-positive breast cancer
From AstraZeneca
Via Business Wire
News headline image
IMJUDO® (tremelimumab) in Combination With IMFINZI® (durvalumab) Approved in the US for Patients With Unresectable Liver Cancer
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca Announces Winners of Fourth Annual Cancer Community Awards
From AstraZeneca
Via Business Wire
News headline image
Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway
From Ikena Oncology, Inc.
Via GlobeNewswire
News headline image
Alexion aims to advance NMOSD treatment landscape with exceptional ULTOMIRIS® (ravulizumab-cwvz) efficacy data at ECTRIMS 2022
From Alexion
Via Business Wire
News headline image
Is Illumina Still the Gamechanger in Genomics Sequencing?
Genome sequencing solutions company Illumina (NASDAQ: ILMN) stock has fallen under its pandemic lows. A surprise earnings miss, and lowered guidance has caused 
Via MarketBeat
Topics Earnings Economy Lawsuit
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide... 
Via FinancialNewsMedia
News headline image
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine
From Alexion
Via Business Wire
News headline image
Danicopan (ALXN2040) Add-On to ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) Met Primary Endpoint in ALPHA Phase III Trial for Patients with Paroxysmal Nocturnal Hemoglobinuria Who Experience Clinically Significant Extravascular Hemolysis
From Alexion
Via Business Wire
News headline image
AstraZeneca Partners with Jeff Bridges, Kumail Nanjiani, and Emily V. Gordon to Educate the Immunocompromised Community about Added Protection Against COVID-19
From AstraZeneca
Via Business Wire
News headline image
IMFINZI® (durvalumab) plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up
From AstraZeneca
Via Business Wire
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer
From AstraZeneca
Via Business Wire
News headline image
IMFINZI® (durvalumab) and tremelimumab with chemotherapy demonstrated sustained survival benefit in metastatic non-small cell lung cancer, nearly doubling the number of patients alive after three years vs. chemotherapy
From AstraZeneca
Via Business Wire
News headline image
TAGRISSO® (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer
From AstraZeneca
Via Business Wire
News headline image
LYNPARZA® (olaparib) in Combination with Bevacizumab, and as a Monotherapy, Demonstrates Clinically Meaningful Survival Benefit in 1st-Line Advanced Ovarian Cancer Across Two Phase III Trials
From AstraZeneca
Via Business Wire
News headline image
IMFINZI® (durvalumab) Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Patients with Advanced Biliary Tract Cancer
From AstraZeneca
Via Business Wire
News headline image
New data show FARXIGA significantly lowers the risk of cardiovascular death in patients with heart failure
From AstraZeneca
Via Business Wire
News headline image
FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022
From AstraZeneca
Via Business Wire
News headline image
LYNPARZA® (olaparib) in combination with abiraterone granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer
From AstraZeneca
Via Business Wire
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.